ChemoCentryx CCXI 深 沪
等待开盘 12-18 09:30:00 美东时间
51.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 51.99
- 总市值 37.10亿
- 52周最高 52.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.95
- 委 比 0.00%
- 总股本 7135.59万
- 历史最高 70.29
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.921
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG THOUSAND OAKS, C...
12-12 07:09
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif., Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The div...
12-10 05:01
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The d...
11-01 04:01
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Ast...
10-18 04:00
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenN...
10-06 21:00
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The plan...
09-26 21:00
Immuneering Names Thomas Schall Chairman Of The Board, Replaces Ben Zeskind In Leadership Transition
Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors.Dr.
09-16 19:12
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The div...
08-02 04:01
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., Jun...
06-30 21:00
United Company RUSAL Receives AAA Credit Rating from CCXI
United Co RUSAL ( ($HK:0486) ) has issued an update. United Company RUSAL has b...
06-05 22:40
